<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03821701</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU1AF-CRF-2018-019</org_study_id>
    <nct_id>NCT03821701</nct_id>
  </id_info>
  <brief_title>Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure</brief_title>
  <official_title>A Multicenter, Randomized Controlled Trial of Angiotensin-Neprilysin Inhibition (ARNI) in the Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baoji Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized controlled multicenter clinical trial, in which about 340 patients
      with newly diagnosed or prior diagnosed chronic heart will be recruited. Patients will be
      randomly divided into Angiotensin-Neprilysin Inhibition (ARNI) group and
      angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB) group.
      All-cause death, cardiac death and re-hospitalization due to heart failure will be evaluated
      in 1, 3, 6, 12 months after recruitment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic heart failure is associated with poor prognosis in cardiac patients, although
      systemic effective drugs has been applied in these patients. European Society of Cardiology
      (ESC) has recommended ARNI Sacubitril/Valsartan as first-line drugs in replacement of ACEI
      (I, B) in 2016 for these patients. While American College of Cardiology and The American
      Heart Association (ACC/AHA) made a first-line recommendation that patients with heart failure
      due to reduced ejection fraction (HFrEF) could be administrated ARNI directly. Hence, we
      apply this trial to find if ARNI could replace ACEI/ARB to provide insights for better
      treatment of chronic heart failure in China. This study is a randomized controlled
      multicenter clinical trial, in which about 340 patients with newly diagnosed or prior
      diagnosed chronic heart will be recruited. Patients will be randomly divided into
      Angiotensin-Neprilysin Inhibition (ARNI) group and ACEI/ARB group. All-cause death, cardiac
      death and re-hospitalization due to heart failure will be evaluated in 1, 3, 6, 12 months
      after recruitment. Other safety assessment including left ventricular ejection fraction
      (LVEF), 6 minutes walk test will be followed up as well.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</time_frame>
    <description>Composite outcomes of all-cause death including cardiac death and re-hospitalization due to heart failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Six-minutes walking test</measure>
    <time_frame>Test in 1, 3, 6, 12 months comparing to the baseline.</time_frame>
    <description>A test evaluating cardiac function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF</measure>
    <time_frame>Test in 1, 3, 6, 12 months comparing to the baseline.</time_frame>
    <description>Left ventricular ejection fraction.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Newly diagnosed HFrEF ARNI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Newly diagnosed HFrEF patients will be administered ARNI Entresto according to the clinical condition among the whole study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Newly diagnosed HFrEF ACEI/ARB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Newly diagnosed HFrEF patients will be administered ACEI/ARB according to the clinical condition among the whole study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prior diagnosed HFrEF ARNI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prior diagnosed HFrEF patients will be administered ARNI Entresto according to the clinical condition among the whole study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prior diagnosed HFrEF ACEI/ARB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prior diagnosed HFrEF patients will be administered ACEI/ARB according to the clinical condition among the whole study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entresto</intervention_name>
    <description>Sacubitril Valsartan Sodium Tablets, 100mg bid, among whole study</description>
    <arm_group_label>Newly diagnosed HFrEF ARNI</arm_group_label>
    <arm_group_label>Prior diagnosed HFrEF ARNI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACEI/ARB</intervention_name>
    <description>Choose one of ACEI/ARB according to the clinical condition among the whole study.</description>
    <arm_group_label>Newly diagnosed HFrEF ACEI/ARB</arm_group_label>
    <arm_group_label>Prior diagnosed HFrEF ACEI/ARB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18

          -  HFrEF, defined as LVEF≤40% and New York Heart Association (NYHA) class ≥ II.

          -  Plasma NT-proBNP ≥ 600 pg/ml, or NT-proBNP ≥ 400 pg/ml if patients have been
             hospitalized for heart failure in 12 months.

          -  If patients have been taking ACEI/ARB at recruitment, a stable dose equivalent to at
             least 10mg/day of enalapril will be required.

          -  Volunteer for the study and sign the informed consent.

        Exclusion Criteria:

          -  Symptomatic hypotension, systolic blood pressure &lt; 95 mmHg at baseline.

          -  eGFR &lt; 30 ml(/min*1.73m2) at baseline.

          -  Serum potassium &gt; 5.4 mmol/L at baseline.

          -  Contraindication of ACEI or ARB.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yihui Xiao</last_name>
    <role>Study Director</role>
    <affiliation>First Affiliated Hospital Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yihui Xiao</last_name>
    <phone>+86 13572236467</phone>
    <phone_ext>+8613572236467</phone_ext>
    <email>sbw_514@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yihui Xiao</last_name>
    <phone>+8613572236467</phone>
    <phone_ext>+8613572236467</phone_ext>
    <email>sbw_514@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yihui Xiao</last_name>
      <phone>+8613572236467</phone>
      <email>sbw_514@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 27, 2019</study_first_submitted>
  <study_first_submitted_qc>January 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Shakurba valsartan</keyword>
  <keyword>Heart failure</keyword>
  <keyword>ACEI/ARB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

